Review for 10.1186/s12876-017-0656-z (2017)

Reviewer ’s report  
 
Title:  Survival benefit of transarterial chemoemboliza tion in patients with metastatic 
hepatocellular carcinoma: a single center experience  
 
Version: 0 Date: 01 Jun 2017 
 
Reviewer:  Giovanni  Tarantino  
 
Reviewer’s report:  
 
Being the severity of chronic liver disease the main clue for the survival, Authors should better 
details the C_P  classification, according to recent articles, i.e., What are the implications of the 
spontaneous spleno -renal shunts in liver cirrhosis?  
 
BMC Gastroenterol. 2009 Nov 24;9:89.  
 
Blood ammonia levels in liver cirrhosis: a clue for the presence of portosyste mic collateral veins.  
 
BMC Gastroenterol. 2009 Mar 17;9:21  
 
What does....Others... in viral etiology stand for?  
 
All in all, I haven't seen many cases of HCC in criptogenetic cirrhosis (Post -NASH). A comment 
is mandatory taking into account the pandemic of t he so -called metobesity.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
No 
 
Does the work include the nec essary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess  any statistics in the manuscript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further 
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an 
organisation that may in any way gain or lose financially from the publication of this 
manuscript, either now or in the future?  
 
2. Do you hold any  stocks or shares in an organisation that may in any way gain or lose 
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the 
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below. If your reply is yes to any, please give details below.  
 
'I declare that I have no competing interests'  
 
I agree to th e open peer review policy of the journal. I understand that my name will be included 
on my report to the authors and, if the manuscript is accepted for publication, my named report 
including any attachments I upload will be posted on the website along with  the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be included as confidential comments 
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal